Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
5.59
+0.07 (1.27%)
Apr 28, 2026, 4:00 PM EDT - Market closed

Aardvark Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22
Net Income
-57.59-20.59-7.21-13.56
Depreciation & Amortization
0.040.02-0.11
Loss (Gain) From Sale of Investments
-1.30.121.222.32
Stock-Based Compensation
3.950.440.310.41
Provision & Write-off of Bad Debts
-0.120.760.49
Other Operating Activities
0.380.24-0.831
Change in Accounts Payable
0.240.80.780.03
Change in Other Net Operating Assets
0.120.78-0.86-1.34
Operating Cash Flow
-54.17-18.09-5.82-10.54
Capital Expenditures
-0.1-0.11--
Investment in Securities
-49.57-11.89--
Other Investing Activities
----1
Investing Cash Flow
-49.67-12--1
Issuance of Common Stock
91.640.33-0.23
Other Financing Activities
-2.39-3.34--
Financing Cash Flow
89.2581.99-0.23
Net Cash Flow
-14.5951.91-5.82-11.32
Free Cash Flow
-54.27-18.2-5.82-10.54
Free Cash Flow Per Share
-2.77-4.55-1.47-2.71
Levered Free Cash Flow
-31.18-10.67-3.54-
Unlevered Free Cash Flow
-31.18-10.67-3.54-
Change in Working Capital
0.361.57-0.08-1.31
Source: S&P Capital IQ. Standard template. Financial Sources.